Save time and jump to the most important pieces.
EMERYVILLE, Calif., Sept. 27, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding diversity of antibodies customers can discover on the Beacon® optofluidic platform. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists
Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression.
New Beacon platform data to be presented by Genovac at Discovery on Target 2023 Poster and podium presentation featuring the Beacon platform to be presented at Annual Festival of Biologics Basel Conference & Exhibition EMERYVILLE, Calif., Sept. 20, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic technologies, along with customer partners, at two upcoming cell biology conferences. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advan
Strategic Alternatives Process Continuing; Board Focused on Maximizing Stockholder Value EMERYVILLE, Calif., Aug. 14, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the second quarter ended June 30, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scien
EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), the functional cell biology company, today announced that the Company will be reporting financial results for the second quarter 2023 after market on Monday, August 14, 2023. CELL) is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. (PRNewsfoto/PhenomeX)" alt="PhenomeX (NASDAQ:CELL) is empowering scientists to leverage the fu
Company provides full year 2023 financial guidance EMERYVILLE, Calif., May 11, 2023 /PRNewswire/ -- PhenomeX, Inc. (NASDAQ:CELL), a life sciences tools company, today reported financial results for the first quarter ended March 31, 2023. Following the completion of Berkeley Lights' acquisition of IsoPlexis on March 21, 2023, the newly combined company was rebranded as PhenomeX and is positioned to be the leading provider of life sciences solutions that have the greatest impact in advancing the era of the phenome as the next revolution in biology and medicine unfolds. Its brand reflects the Company's mission to empower scientists to leverage the full potential of each cell and drive the next
Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (NASDAQ:CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression. CELL) is empowering scientists to lever
Fully quantitative bulk and comprehensive single cell proteomics are now both available on the IsoSpark platform
On Monday, Cathie Wood-led Ark Invest made a significant move by continuing its buying spree of Archer Aviation Inc (NASDAQ:ACHR) shares. The investment firm purchased shares worth nearly $3.9 million, emphasizing its bullish stance on the flying car company. The Archer Aviation Trade: In total, Ark purchased nearly 604,000 shares of Archer Aviation. The transaction was valued at almost $3.9 million, based on the stock’s closing price of $6.39 on Monday. The purchases were made through ARK Innovation ETF (NYSE:ARKK), ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), and ARK Space Exploration & Innovation ETF (BATS:ARKX).Ark Invest’s recent acquisitions of Archer Aviation shares co
EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- PhenomeX (NASDAQ:CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately. Mr. Silvester most recently served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific and brings more than 25 years of experience in the life sciences tools industry as an executive and board member. "Peter's wealth of knowledge within the life sciences industry and experience in global business and commercial oper